Function Therapeutics is pioneering a new class of anti-inflammatory drugs known as PARmodulins, which specifically target Protease-Activated Receptor 1 (PAR1) signaling. These small molecules are designed to selectively inhibit certain inflammatory pathways while simultaneously promoting protective anti-inflammatory responses. By modulating the activity of PAR1, which plays a crucial role in various inflammatory diseases, including kidney disease and sepsis, PARmodulins have the potential to offer novel therapeutic options for conditions that currently lack effective treatments.

The company’s research focuses on the unique properties of protease-activated receptors (PARs), a family of G protein-coupled receptors that are activated by proteases like thrombin and trypsin. Function Therapeutics has identified small molecules that can either inhibit or activate specific signaling pathways associated with PAR1, leading to reduced platelet activation and inflammatory responses in endothelial cells. This innovative approach is supported by collaborations with leading experts in various fields, enhancing the development of therapies aimed at addressing urgent medical needs in inflammation-driven diseases.

United States

Developing anti-inflammatory drugs that modify Protease-Activated Receptor signaling (PARmodulins). Parmodulins are small molecules that can selectively block certain aspects of inflammation while promoting anti-inflammatory signals mediated by protease-activated receptor 1 (PAR1).

Function Therapeutics

Company Details